Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shilpa MedicareNSE:SHILPAMED -2.76%76 Days Inventory is 235.72 as of Mar. 2026, which is 19% below its 10-year median of 289.43. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 76/100 and a GF Value™ of ₹387.78 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 923 Drug Manufacturers companies, Shilpa Medicare ranks worse than 84.83% on this metric.
The historical rank and industry rank for Shilpa Medicare's Days Inventory or its related term are showing as below:
NSE:SHILPAMED'
s Days Inventory Range Over the Past 10 Years
Min: 159.13 Med: 289.43 Max: 366.17
Current: 306.42
During the past 13 years, Shilpa Medicare's highest Days Inventory was 366.17. The lowest was 159.13. And the median was 289.43.
NSE:SHILPAMED's Days Inventory is ranked worse than 84.83% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.38
vs NSE:SHILPAMED: 306.42
Shilpa Medicare's Days Inventory
declined
from Mar. 2025 (303.84) to Mar. 2026 (235.72).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shilpa Medicare's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.39.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shilpa Medicare's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.84.
Shilpa Medicare (NSE:SHILPAMED) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Shilpa Medicare's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shilpa Medicare's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Shilpa Medicare Days Inventory Related Terms
Shilpa Medicare Days Inventory Historical Data
* Premium members only.
The historical data trend for Shilpa Medicare's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:SHILPAMED vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Shilpa Medicare's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shilpa Medicare Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shilpa Medicare's Days Inventory distribution charts can be found below:
* The bar in red indicates where Shilpa Medicare's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shilpa Medicare (NSE:SHILPAMED) has a Days Inventory of 235.72 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shilpa Medicare and its competitors. This is 19% below median its historical median of 289.43. Over the past decade, Shilpa Medicare's Days Inventory has ranged from 159.13 to 366.17. According to the industry distribution chart, Shilpa Medicare ranks #783 out of 923 companies in the Drug Manufacturers industry, placing it in the top 84.8%.
Is Shilpa Medicare's Days Inventory too high?
Shilpa Medicare's current Days Inventory of 235.72 is 19% below median its 10-year median of 289.43. Over the past 10 years, this metric has ranged from a low of 159.13 to a high of 366.17. The Drug Manufacturers industry median Days Inventory is 164.38. Shilpa Medicare's value of 235.72 is 43.4% above this industry median. Based on the distribution chart, Shilpa Medicare ranks #783 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shilpa Medicare ranks #783 out of 923 companies for Days Inventory. This places Shilpa Medicare in the lower half of its industry. The industry median Days Inventory is 164.38. Shilpa Medicare's value of 235.72 is 43.4% above this benchmark. Historically, Shilpa Medicare's own Days Inventory has ranged from 159.13 to 366.17 over the past decade. While the company's 10-year median is 289.43 vs. the industry median of 164.38, Shilpa Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.38, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shilpa Medicare's current Days Inventory of 235.72 is 43.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shilpa Medicare and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shilpa Medicare's current Days Inventory is 235.72, which is 19% below median its own 10-year median of 289.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.78, compared to a current price of ₹620.25 — trading 59.9% above its estimated fair value. The current Days Inventory is 235.72, which is 19% below median its 10-year median of 289.43 and 43.4% above the Drug Manufacturers industry median of 164.38. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current Days Inventory is 235.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?
Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued.
The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78.
GuruFocus considers Shilpa Medicare to be Significantly Overvalued.
Key valuation signals for NSE:SHILPAMED:
Days Inventory: 235.72 (19% below median its 10-year median of 289.43)
GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
Industry Position: 43.4% above the Drug Manufacturers median (#783 of 923)
No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for NSE:SHILPAMED
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SHILPAMED has been successfully added to your 
